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Abstract The current paper presents a position state-
ment of the Dutch Working Group of Transcatheter
Heart Valve Interventions that describes which pa-
tients with aortic stenosis should be considered for
transcatheter aortic valve implantation and how this
treatment proposal/decision should be made. Given
the complexity of the disease and the assessment of its
severity, in particular in combination with the contin-
uous emergence of new clinical insights and evidence
from physiological and randomised clinical studies
plus the introduction of novel innovative treatment
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modalities, the gatekeeper of the treatment proposal/
decision and, thus, of qualification for cost reimburse-
ment is the heart team, which consists of dedicated
professionals working in specialised centres.
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Introduction
Aortic valve stenosis is a common valvular heart dis-
ease, the prevalence of which increases with age, and
is associated with a dismal prognosis and quality of
life in the presence of symptoms and/or left ventricu-
lar (LV) impairment [1]. Survival and quality of life can
only be improved by aortic valve replacement, with
surgical aortic valve replacement (SAVR) having been
the unique and undisputable reference procedure for
many decades. Since 2002 a less invasive procedure
has been available that consists of the implantation of
a trileaflet bioprosthetic valve mounted in a metallic
scaffold at the base of the aortic root, predominantly
via the common femoral artery, and is termed tran-
scatheter aortic valve implantation (TAVI, Europe) or
replacement (TAVR, USA) [2]. In contrast to SAVR,
TAVI is a beating heart procedure without the need
for general anaesthesia, sterno- or thoracotomy, aor-
tic cross-clamping, cardiac arrest and extracorporeal
circulation or other forms of circulatory support [3].
TAVI was conceptualised by Henning R. Andersen
(Denmark), whose proposal was not accepted for pub-
lication several times, as the topic was considered to
have too low a priority. Hence TAVI was first executed
in clinical practice by Alain Cribier and co-workers in
2002 (France) [2, 4]. The Netherlands quickly adopted
this innovative treatment and played a vital role in
further refinement and simplification of TAVI without
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surgical access and circulatory support (i.e. fully per-
cutaneous TAVI, which experienced its world premiere
in October 2006) [5, 6] Thereafter, TAVI was quickly
embraced, leading to an explosive increase in its use,
outnumbering SAVR procedures and boosting the use
of bioprosthetic valves during SAVR even in patients
in whom—mainly because of their age—mechanical
valves were considered the preferred type [7, 8].
In contrast to percutaneous coronary intervention
(PCI), which was first performed in a young male pa-
tient with a so-called low-risk coronary artery lesion,
TAVI was first applied in a patient who was rejected
for SAVR [2]. Clinical practice followed this paradigm
and TAVI was considered only in patients who were
not candidates for SAVR or at prohibitive risk if under-
going SAVR. Consequently, the first randomised clini-
cal trials that directly compared safety and efficacy of
TAVI and SAVR were conducted in this category of pa-
tients [9, 10]. Based upon the findings, TAVI became
the recommended treatment for elderly patients with
aortic stenosis, who are considered not to be candi-
dates for surgery or poor surgical candidates or at in-
creased operative risk for mortality or complications
[11, 12].
In the Netherlands there is currently a debate
among stakeholders in care—from healthcare provi-
ders and their clinical and scientific societies, policy
makers and insurance companies to patients and
their associated societies—concerning in which pa-
tients TAVI should be considered the preferred treat-
ment and, more specifically, whether TAVI in patients
with aortic stenosis for whom SAVR involves an in-
termediate or (more recently) also low risk should
constitute medical care that qualifies them for cost
reimbursement.
This question is not only of clinical or clinical-sci-
entific interest, it is also highly relevant and even criti-
cal for the organisation of care and resource planning
both from the perspective of the professionals and
their institutions who deliver care (hospitals) and pol-
icy makers and affiliated institutions or organisations.
For instance, a recent study reported that approxi-
Table 1 Landmark studies [14–18] comparing transcatheter
aortic valve implantation (TAVI) with surgical aortic valve re-
placement (SAVR) in patients with aortic stenosis at intermedi-
ate (PARTNER 2A, SURTAVI) and low risk (PARTNER 3, Evolut)
if undergoing SAVR
PARTNER 2A SURTAVI Thourani et al Partner 3 Evolut
Publication 2016 2016 2017 2019 2019
Design RCT RCT Propensity matched
analysis
RCT RCT
Hypothesis TAVI non-inferior TAVI non-inferior n.a. TAVI non-inferior TAVI non-inferior
Primary end-
point
All-cause death or dis-
abling stroke at 2 years
All-cause death or dis-
abling stroke at 2 years
All-cause death, stroke,
≥moderate PVL at 1 year
All-cause death, stroke,
or rehospitalisation at
1 year
All-cause death or dis-
abling stroke at 2 years
Risk assess-
ment
By heart team
(guided by STS 4–8)
By heart team
(guided by STS 3–15)
By heart team
(guided by STS>4)
By heart team
(guided by STS<4)
By heart team
(guided by STS<3)
No. of patients 2032 1746 2021 1000 1468
PVL paravalvular leak, RCT randomised controlled study, STS Society of Thoracic Surgery risk score
mately 42% of patients with symptomatic aortic steno-
sis do not undergo SAVR and notwithstanding being
deemed candidates for TAVI, 38% did not receive TAVI
but medical therapy [13]. In addition, the number of
patients per annum who are candidates for TAVI in
the EU is estimated to be 114,757 (95% confidence
interval (CI) 69,380–172,799—Netherlands: 3614 pa-
tients (95% CI 2185–548)) when using current indica-
tions. This number would increase by 7% to 122,402
(95%CI 38,170–93,322) if all intermediate-risk patients
were to receive TAVI. If TAVI became the preferred
treatment not only for intermediate-risk patients but
also for patients >75 years at low surgical risk, there
would be a further 50% increase of TAVI candidates to
177,462 per annum (95% CI 110,059–260,576; Nether-
lands: 5524 patients (95% CI 3467–8126)).
Given the above, the concern of the Dutch Health-
care Authorities and the question as to whether the
cost of TAVI should be reimbursed in patients with
aortic stenosis for whom SAVR involves an intermedi-
ate risk is understandable.
Clinical-scientific evidence in ‘intermediate-risk’
patients
The best evidence available to answer the question
are the results and conclusions of four landmark ran-
domised controlled trials (RCTs) that directly com-
pared TAVI with SAVR in patients at intermediate and
low surgical risk [14–18]. The studies and their results
are summarised in Tab. 1, 2 and 3. Considering the
primary endpoint, the conclusion is that TAVI is non-
inferior to SAVR and superior when transfemoral ac-
cess is possible in patients at intermediate and low
surgical risk. In addition, a different pattern of other
adverse outcomes is observed with TAVI than with
SAVR, such as a higher incidence of permanent pace-
maker implantation after TAVI (especially when using
self-expanding valves) but a higher incidence of bleed-
ing, acute kidney insufficiency and new-onset atrial
fibrillation after SAVR (Tab. 2 and 3).
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Table 2 Components of outcomes, landmark studies [14–18]
comparing transcatheter aortic valve implantation (TAVI) with
surgical aortic valve replacement (SAVR) in patients with aortic
stenosis at intermediate (bold) and low risk (italic) if undergo-
ing SAVR
PARTNER 2A SURTAVI Thourani et al PARTNER 3 Evolut
TAVI SAVR TAVI SAVR TAVI SAVR TAVI SAVR TAVI SAVR
Age 81.5
(6.7)
81.7
(6.7)
79.9
(6.2)
79.8
(6.0)
81.9
(6.6)
81.6
(6.8)
73
(6)
73
(6)
74
(6)
74
(6)
STS score 5.8
(2.1)
5.8
(2.1)
4.4
(1.5)
4.5
(1.6)
5.2
(4.3–6.3)
5.4
(4.4–6.7)
1.9
(0.7)
1.9
(0.6)
1.9
(0.7)
1.9
(0.7)
Deatha 3.4 4.0 2.2 1.7 1.1 4.0 0.4 1.1 0.5 1.3
Death at FU 16.3 17.9 11.4 11.6 7.4 13.0 1.0 2.5 2.4 3.0
All strokea 6.5 6.5 3.4 5.6 2.7 6.1 0.6 2.4 3.4 3.4
All stroke at FU 12.8 11.1 6.2 8.4 4.6 8.2 1.2 3.1 4.1 4.3
Disabling strokea 3.2 4.4 1.2 2.5 1.0 4.4 0.0 0.4 0.5 1.7
Disabling stroke at FU 6.2 6.5 2.6 4.5 2.3 5.9 0.2 0.9 0.8 2.4
Major bleedinga 10.5 46.9 12.2 9.3 4.6 46.7 3.6 24.5 2.4 7.5
Bleeding at FU 17.3 50.2 nr nr nr nr 7.7 25.9 3.2 8.9
AKI a 1.2 3.3 nr nr 0.5 3.3 0.4 1.8 0.9 2.8
AKI at FU 3.8 6.4 nr nr nr nr nr nr 0.9 2.8
New-onset A. FIBa 9.1 28.3 12.9 43.4 5.0 28.3 5.0 39.5 7.7 35.4
New A. FIB at FU 11.3 29.3 nr nr 5.9 29.2 7.0 40.9 9.8 38.3
PPI* 8.6 7.3 25.9 6.6 10.2 7.3 6.6 4.1 17.4 6.1
PPI at FU 12.0 10.8 nr nr 12.4 9.4 7.5 5.5 19.4 6.7
Age and STS are expressed using either mean (±SD) or median (IQR)
Outcomes are expressed as relative number
AKI acute kidney failure, A. FIB atrial fibrillation, FU follow-up, nr not reported, PPI permanent pacemaker implantation, STS Society of Thoracic Surgery
aClinical endpoint at 30 days
Thourani et al. used the PARTNER 2 observational
and PARTNER 2A randomised trial to compare out-
come (follow-up duration 12 months) between TAVI
and SAVR in intermediate-risk patients [16]. To correct
for confounding in the statistical comparison—due
to imbalance in baseline characteristics—propensity
scores were calculated for each individual patient rep-
resenting the likelihood of being treated with TAVI fol-
lowed by partitioning into five quintiles: 1, lowest 20%
likelihood; 5, highest 20% likelihood. In each quin-
tile, patients undergoing TAVI had a lower incidence
of the composite primary endpoint than patients who
underwent SAVR (ranging from –14.5% in quintile 1 to
–4.3% in quintile 5). Moreover, TAVI was superior to
SAVR for the composite endpoint (weighted difference
of proportions –9.2%, 95% CI –13.0 to –5.4; p< 0.0001)
and for the individual outcomes of death (–5.2%, –8.0
to –2.4; p=0.0003) and stroke (–3.5%, –5.9 to –1.1;
p= 0.0038). SAVR was superior to TAVI for ≥moderate
aortic regurgitation (1.2%, 0.2–2.2; p=0.01). Based on
their findings the authors conclude that ‘TAVR should
be considered as the preferred alternative to SAVR in
intermediate-risk patients and an expected extension
of indication to the surgical candidate in the near fu-
ture’.
A different approach from scientific societies
and medical professionals
This committee believes, however, that the question of
the Dutch Healthcare Authorities should be rephrased
more generically, namely as ‘Which patients with aor-
tic stenosis should be considered for TAVI and how
should treatment decisions be made?’ The reasons for
reformulating the question are elaborated in the fol-
lowing paragraphs, which address a number of issues
related to the complexity of medical decision-mak-
ing in the individual patient and the fast and inces-
sant technological evolution and innovations in aortic
valve replacement therapy affecting clinical medicine,
followed by the conclusions and recommendations of
the Dutch Working Group of Transcatheter Heart In-
terventions.
Risk models—can we define risk in the individual
patient?
The medical, medical-scientific and non-medical
communities use a risk score or a risk score model
to categorise patients into various risk categories on
the basis of an arbitrary cut-off value. Various cut-off
values are used. In the landmark RCTs, the Society
of Thoracic Surgery (STS) risk score (risk of death
at 30 days after surgery) was used [14–17]. For the
definition of intermediate risk, the PARTNER 2A study
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Table 3 Primary endpoint
of landmark studies [14–18]
comparing transcatheter
aortic valve implantation
(TAVI) with surgical aortic
valve replacement (SAVR) in
patients with aortic stenosis
at intermediate and low risk
if undergoing SAVR
PARTNER 2A
All TAVI patients SAVR Hazard ratio (95% CI)
Intention to treat 19.3 21.1 0.89 (0.73–1.0)
As treated 18.9 21.0 0.87 (0.71–1.07)
Transfemoral TAVI patients SAVR –
Intention to treat 16.8 20.4 0.79 (0.62–1.00)
As treated 16.3 20.0 0.78 (0.61–0.99)
SURTAVI
All TAVI patients SAVR Δ (95% CI)
Intention to treat 12.6 14.0 –1.4 (–5.2 to 2.3)
As treated – – –
PARTNER 3
Transfemoral TAVI (= all patients) SAVR –
As treated 8.5 15.1 –6.6 (–10.8 to –2.5)
Evolut
All TAVI patients SAVR Δ (95% CI)
As treated 5.3 6.7 –1.4 (–4.9 to 2.1)
Primary endpoint is expressed as relative number. CI confidence interval
used a cut-off value of STS ≥4–8% while the SURTAVI
trial used a margin of 3–15%. Low risk was defined
by STS <3 or 4 [16, 17]. The European Society of Car-
diology (ESC) left the original three-category system
(high, intermediate and low risk) and proposes to
break down patients into low or non-low risk. Low
risk is defined by a STS or EuroSCORE 1 score <4% or
a logistic EuroSCORE <10%. Non-low risk is conse-
quently defined by a STS or EuroSCORE 1 score of ≥4
or a logistic EuroSCORE ≥10%.
Interestingly, neither the STS nor the Euro- or
logistic EuroSCORE has been designed for patients
undergoing TAVI but for patients undergoing open-
heart surgery in general, while a model performs best
when developed from a population that undergoes the
specific procedure. The use of both the STS and the
EuroSCORE in patients referred for TAVI has, there-
fore, been questioned openly. There are currently
two TAVI-specific risk scores, the FRANCE-2 model
and the Risk Prediction model proposed by the STS/
American College of Cardiology (ACC) Transcatheter
Valve Therapy (TVT) Registry [19, 20]. The latter is
the most robust and sound one and consists of a de-
velopment and validation model. The development
model is based upon a series of 13,718 out of 13,887
Table 4 Components of primary endpoint of propensity-
matched analysis comparing transcatheter aortic valve
implantation (TAVI) with surgical aortic valve replacement
(SAVR) in patients with aortic stenosis at intermediate risk
if undergoing SAVR
All TAVI patients SAVR Transfemoral TAVI SAVR
Death 7.4 13.0 6.5 12.2
Stroke 4.6 8.2 4.3 8.6
≥moderate
PVL
1.5 0.4 nr nr
nr not reported, PVL paravalvular leak
patients (only 1.2% patients with missing data) who
received TAVI outside the landmark RCTs between
2011 and 2014at 265 sites in the USA. The validation
model is based upon 6868 out of 6877 patients (only
9 patients with missing data) who received TAVI in
2014at 314 sites. At variance with the STS and Eu-
roSCORE, the endpoint or outcome was mortality at
discharge, which was chosen as such given its clinical
relevance, easiness to define and collect. The devel-
opment task force of the TVT Registry selected an
initial set of covariates that was reduced to 9 after sta-
tistical analysis and TVT Registry Steering Committee
evaluation. Considering the limitations (i.e. single
short-term endpoint, no inclusion of prediction of
neurological deficit, exclusion of covariates that also
affect the primary endpoint, such as frailty) the main
finding was that the STS/ACC TVT risk model showed
excellent calibration in the overall number of patients
undergoing TAVI and in various clinical subsets. Also,
the STS/ACC TVT model performed better than the
STS and EuroSCORE models. Given the limitations
of the current model, the investigators are continuing
to refine and improve the model by including the
prediction of 1-year mortality in addition to non-fatal
outcomes and the inclusion of more covariates so
as to offer an instrument to help physicians in the
delivery of patient-centred care.
Nevertheless, it is acknowledged by the experts and
medical professionals that any risk model will remain
a distant abstract of the complex reality of clinical de-
cision-making, as no model will be able to include all
covariates affecting mortality and non-fatal compli-
cations during and shortly after cardiac interventions
and will always fall short as regards accurately pre-
dicting the risk in the individual patient. For that rea-
son, the medical community and their scientific soci-
eties both in the EU and USA emphasise that a model
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should not indicate which patient is a candidate for
TAVI but to be considered and used as a single ele-
ment in the selection process in concert with all the
other information collected by the physician when
he/she sees and examines the patient (clinical judge-
ment based upon a cardiac-specific and general his-
tory and physical examination) in addition to techni-
cal assessments such as laboratory (e.g. haemoglobin,
kidney function, NT-proBNP . . . ) and cardiovascular
imaging [11, 12]. The deficiencies of risk models were
recognised during the design phase of the landmark
RCTs and are the reason why the heart team received
a central and dominant role in the process of patient
selection for aortic valve replacement therapy [14–17].
The heart team: defining indication and optimal
treatment modality in the individual patient
To address the deficiencies of risk models, the med-
ical-scientific organisations in both the EU and USA
strongly endorse the role of the heart team in making
the treatment decision [12]. The update of the 2017
European and American guidelines explicitly states
that ‘the core principle in the ESC approach is to em-
phasise a complex decision process with a list of spe-
cific factors to be considered in each patient, rather
than defining broad patient groups that should un-
dergo TAVI or SAVR’ [12]. The guidelines first of all
state that aortic valve interventions should be per-
formed only in centres with both departments of car-
diology and cardiac surgery on site and with struc-
tured collaboration between the two, including a heart
team. The choice of the intervention must be based
upon careful individual evaluation of technical suit-
ability and weighing-up of the risks and benefits of
each modality. These should be discussed with the
patient and their family in accordance with the policy
of the healthcare authorities to involve the patient and
family in the decision-making process, as discussed
below. In addition, the local expertise and outcomes
for the given intervention must be taken into account.
The 2017 ESC guidelines help the physician and heart
team by providing a list of variables to be considered,
many of which are not included as covariates in the
current risk prediction models [11, 12].
The concept of the heart team and, thus, a collabo-
rative approach between interventional cardiologists
and cardiothoracic surgeons to jointly deliver appro-
priate care in a timely manner while minimising un-
necessary investigations and procedures was recog-
nised in the early 2000s for patients with (complex)
cardiac disease. In the resulting joint publications
of the scientific societies (cardiology, cardiothoracic
surgery) in both the EU and USA, recommendations
were provided for the delivery and organisation of care
in 2006 and 2010 [21].
The dominant role of the heart team is confirmed
by the ESC Working Group on Valvular Heart Dis-
ease, which goes one step further by recommending
the creation of Heart Valve Clinics (HVC), in which
a group of healthcare professionals with expertise in
heart valve disease (HVD) work in a dedicated envi-
ronment to provide specialised and centralised eval-
uation, care and education to patients with HVD [21].
The reason is the observed variability in the degree of
expertise in the management of patients with HVD as-
sociated with inappropriate use of care and facilities
(i.e. under- or overtreatment) due to—among other
factors—the complexity of establishing the correct di-
agnosis (severity of the HVD in particular) and de-
ciding on the correct timing and type of intervention
in a patient with VHD. The objective of creating HVC
is to improve the appropriateness of care (diagnosis,
treatment decision, follow-up) in addition to training
and education of patients and medical professionals.
In accordance with the updated 2017 European and
American guidelines, this committee sees the role of
the heart team as follows:
1. Verification of the correctness of the diagnosis and
the indication for the intervention,
2. Treatment proposal; valve replacement or medical
therapy with
a.written documentation of the motivation for the
treatment proposal in the case of medical therapy
and
b.in the case of valve replacement therapy, written
documentation of the motivation for the pro-
posed mode of valve replacement therapy (i.e.
catheter-based or surgical) and the preferred
valve type (bioprosthetic or mechanical).
Verification of correctness of diagnosis and indication
For this purpose, the presence of an imaging special-
ist during the heart team meeting is essential [11, 12,
21]. His/her presence is particularly important given
the intricacies in not so much the verification of the
presence and aetiology of disease but especially its
severity and effects on the heart and cardiovascular
system. The adagio of Catherine Otto, ‘Listen to the
patient and look at the valve’ or ‘Treat the patient and
not the number’, remains very true, most likely for
many years to come, despite improved understand-
ing of the pathophysiology of the disease process and
its consequences [22, 23]. The effect of LV geome-
try and function in the assessment of the severity of
aortic stenosis is well understood and widely recog-
nised [24]. This is not the case for the presence of
systemic hypertension or other factors affecting ven-
triculo-arterial coupling [25]. Another ongoing debate
is whether asymptomatic patients with severe aortic
stenosis and preserved LV function should be denied
aortic valve replacement therapy [26]. This also holds
for patients with moderately severe aortic stenosis and
impaired LV function.
In clinical practice, cut-off values help to discern
non-severe and severe aortic stenosis and, thus, the
treatment indication. While on a population level
these cut-off values (e.g. antegrade velocity, valve
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area) may be useful to differentiate patient categories
at increased risk of death, they are less useful in
the individual patient due to overlap of these cut-
off values in the various risk groups and—similar
to the assessment of the severity of mitral regurgi-
tation—the dynamic interaction between the valve,
left ventricular and arterial system when measuring
these values. It reinforces the role of the heart team
and HVC in the treatment decision (and selection)
by providing an expert collaborative (medical special-
ities) and integrative approach (patient symptoms,
antecedents, co-morbidity, valve anatomy, function
and consequences—electrocardiography, echocardio-
graphy, laboratory data).
The presence of a geriatrician is recommended par-
ticularly when a patient ≥75 years or younger but with
co-morbid conditions that raise the suspicion of neu-
rocognitive dysfunction and/or frailty is discussed. It
is recommended that such patients are first seen by
the geriatrician before the heart team meeting and
certainly before the final treatment decision so as to
avoid the treatment being futile.
Treatment proposal
The ESC guidelines are to be used as a framework
for decision-making but, as pointed out by the ESC
Guideline Committee, the decision should be indi-
vidualised to each patient’s situation [11, 12]. This
committee recognises that medical decision-making
is changing, with increasing involvement of patient
and family, which is in line with the endorsement of
the development of more patient-centred care pro-
moted by healthcare authorities in both the EU and
USA [27]. As stated by the Food and Drug Administra-
tion (FDA), individual patients may experience the ef-
fects of disease and therapies differently and may have
a unique perspective about diagnostic procedures or
treatments that differ from those of other patients or
their healthcare provider. This is reason why the FDA
and the European Medicines Agency (EMA) created
the FDA/EMA Patient Engagement Cluster, which is
a working group on the importance and role of patient
engagement. For that purpose, the patient-reported
outcome is now being incorporated in the clinical-
scientific evaluation in addition to the standard mea-
sures of safety and efficacy, as it measures the patient’s
response concerning his/her health condition without
caregiver interpretation.
Valve type
Valve type selection should be based upon balancing
the risk of bleeding associated with oral anticoagu-
lant therapy when choosing a mechanical valve and
the risk of structural valve deterioration and the need
for a redo operation or intervention when choosing
a bioprosthetic valve. Both the ESC and American
Heart Association (AHA) guidelines stress this should
be a shared decision-making process in which the pa-
tient’s age, expected longevity and preferences need
to be included (class 1 recommendation). In general,
they recommend a mechanical valve in patients aged
under 50 or 60 and a bioprosthetic valve in patients
aged over 65 or 70 years [12]. It has to be recognised
that valve replacement therapy is the substitution of
a disease with a more benign condition mandating
careful instruction and information of the patient and
structured follow-up. Bioprosthetic valves are increas-
ingly being used in younger patients who—by virtue
of their age—are at higher risk of structural valve de-
terioration [28]. Yet, the use of bileaflet mechanical
valves is associated with a considerable lifetime risk
of valve-related morbidity such as thromboembolism
(18%), bleeding (15%) and reintervention (10%) [29].
Hypo-attenuated leaflet thickening and early-reduced
leaflet motion have been reported in approximately
10% of the patients who underwent advanced imag-
ing after bioprosthetic valve implantation (TAVI) and
replacement (SAVR) [30]. Their clinical significance
remains to be elucidated but they are assumed to be
markers of a thrombotic process triggered by the valve
replacement procedure. This matter is the subject of
a number of RCTs evaluating optimal antithrombotic
therapy after bioprosthetic valve implantation [30].
The above highlights the complexity of current
medical decision-making. The role of the heart team
is to make a balanced decision after careful weighing-
up of the risks and benefits of catheter-based and
surgical aortic valve replacement as suggested by the
ESC guidelines and the ESC Working Group on Valvu-
lar Heart Disease and following the recommendation
of healthcare policies regarding patient involvement.
This committee, therefore, strongly recommends that
the motivation for the treatment proposal made by
the heart team is collected in the electronic patient
dossier for reasons of auditing and verification both
for clinical and clinical-scientific reasons, and should
be accompanied by a shared-decision agreement with
the patient, after a careful discussion on the topic.
Data base: to adequately assess risks and benefit
of proposed treatment modalities—institutional
performance
Since the heart team needs to weigh up the risk and
benefits of the proposed treatment modality, the lo-
cal heart team must be informed about the outcome
of the proposed treatment in the local institution.
This implies a local infrastructure and organisation
of data collection that is capable of providing valid
monitoring and evaluation of care as proposed by
the ESC Working Group on Valvular Heart Disease
[21]. In concordance, participation in a nationally au-
dited registry—in addition to written documentation
of the motivation for the heart team’s treatment pro-
posal—should be the prerequisite for reimbursement
of the care delivered (i.e. medical treatment, catheter-
based or surgical valve replacement therapy).
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The objective of the nationwide registry is to mon-
itor and evaluate the care of patients with VHD re-
ferred to hospitals certified for valvular heart replace-
ment therapy in the Netherlands in addition to the
evolution of care. This implies essentially:
1. definition of aminimal data set that captures the in-
dispensable data of the patient, procedure and ini-
tial follow-up (e.g. at hospital discharge or at 30 days
or whichever comes first) to monitor and evaluate
the outcome and evolution of care,
2. definition of the responsibilities of the persons in-
volved in the organisation and management of the
nationwide data base.
While Europe was the cradle of TAVI, the USA took the
lead in organising and conducting the landmark trials
that have affected and still greatly affect the manage-
ment of patients with VHD (aortic stenosis in particu-
lar) and the creation of a nationwide data registration
system for:
 evaluation of the results of the landmark RCTs
(added value of registry data on outcome in rela-
tion to those of patient populations recruited in the
framework of RCTs in expert cardiac centres),
 post-market surveillance (an FDA prerequisite),
 covering of care (national coverage decision by
the US Centers of Medicare and Medicaid Services
(CMS)).
The EU, and the Netherlands in particular, must fol-
low the mature and professional way in which the
nationwide registry has been organised in the USA.
The US professional medical societies (the Society of
Thoracic Surgeons (STS) and the American College of
Cardiology (ACC)) developed the Transcatheter Valve
Therapy (TVT) Registry in collaboration with the FDA,
CMS and valve manufacturers [31]. The definition of
the data set was based upon the focus of collecting
those data that are critically important to adequately
measure the quality of care:
 TVT Registry hospital participants capture data
but these are collected and stored by the ACC. On
a quarterly basis the ACC transmits the data to an
independent research institute (Duke Clinical Re-
search Institute, DCRI).
 Outcomes are adjudicated by a board-certified car-
diologist at the DCRI using Valve Academic Re-
search Consortium-2 (VARC-2) definitions.
 The DCRI performs analyses for research and publi-
cations.
 AResearch and Publication Committee has been es-
tablished to evaluate and approve research propos-
als and to monitor their progress.
 ARegistry SteeringCommittee overseeing the strate-
gic direction of the registry is composed of physi-
cians appointed from the STS and ACC, FDA and
CMS representatives, and staff members of STS and
ACC.
 A Stakeholder Advisory Committee includes mem-
bers from device manufacturers, patients, con-
sumers, FDA and CMS, physicians and health sys-
tems, and provides meaningful input regarding the
needs and goals of each of the stakeholders.
Such a professional and complete structure and in-
frastructure that guarantees the quality of the data set
in addition to relevant outcome reports is essential.
The Dutch Society of Cardiology and the Society of
Cardiothoracic Surgery endorse this initiative, which
is currently taking place in the Netherlands.
Conclusion/summary
There is currently debate in the Netherlands as to
whether TAVI for patients with aortic stenosis for
whom SAVR would involve an intermediate or cur-
rently also low risk should be considered for reim-
bursement. This committee believes that instead of
using arbitrarily defined quantitative cut-off values
to categorise patients into various risk groups, reim-
bursement of the cost of care should be based upon
the appropriateness of care. Given the complexity of
the disease in terms of diagnosis, treatment decision,
treatment execution and evaluation, this is best done
by a team of experts in VHD (heart team) working
in dedicated centres that qualify for the treatment of
VHD. As elaborated in this article, categorisation of
patients into risk groups falls short when it comes
to the evaluation of the individual patient. Also, the
rapid technological evolution of minimally invasive
treatment of VHD will change the management of
patients with VHD, such as asymptomatic patients or
patients with moderate aortic stenosis and impaired
LV functions. Further developments in indications
may be expected as treatment becomes less and less
invasive while maintaining and even improving the
current outcome measures of safety and efficacy (e.g.
early intervention with the objective of preserving LV
function by avoiding the development of myocardial
fibrosis). Given this outlook, the role of the expert
heart team and heart valve centres is and will be even
more crucial to guarantee the appropriateness of care,
treatment decision and modality in particular. It ob-
viates the need for repetitive reevaluation of whether
a novel treatment modality or patient category meets
the requirements of reimbursement of the costs of
treatment.
In accordance with the medical-clinical and clin-
ical-scientific societies of cardiology and cardiotho-
racic surgery in both the EU and USA, the Dutch
Working Group of Transcatheter Heart Interventions
recommends that the Dutch Healthcare Authorities
provide coverage of every patient with aortic stenosis
who will be or has been treated with TAVI, provided:
 The dossier of the patient has been discussed in
the multidisciplinary heart team meeting of an
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institution that qualifies to perform transcatheter
heart interventions in accordance with the Compe-
tence Document of the Dutch Society of Cardiology
(NVVC) and the Dutch Society of Thoracic Surgery
(NvT).
 The treatment decision and modality are based
upon the Indication Document of the NVVC and
NvT (appendix 2—a document that is annually re-
vised and updated if necessary by the Dutch Work-
ing Group of Transcatheter Heart Interventions on
the basis of clinical evidence published in peer-
reviewed journals and guidelines of scientific so-
cieties) which are captured in the electronic pa-
tient file, including the motivation for these, in such
a way that treatment decision, modality and moti-
vation are suitable for retrospective verification for
internal and external auditing.
 The institution that performs transcatheter heart
interventions participates in a nationwide prospec-
tive registry that—for reasons of independence and
quality—complies with the organisational infras-
tructure and set-up of the ACC/AHA TVT Registry.
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